Global Oncology Biosimilars Market Professional Survey Report 2019

2 Global Oncology Biosimilars Quarterly Market Size Analysis

• 2.1 Oncology Biosimilars Business Impact Assessment - COVID-19
  • 2.1.1 Global Oncology Biosimilars Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Oncology Biosimilars Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Oncology Biosimilars Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Oncology Biosimilars Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Oncology Biosimilars Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Oncology Biosimilars Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Oncology Biosimilars Market
• 3.5 Key Manufacturers Oncology Biosimilars Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Oncology Biosimilars Segments, By Type

• 4.1 Introduction
  • 1.4.1 mAb
  • 1.4.2 Immunomodulators
  • 1.4.3 Hematopoietic Agents
  • 1.4.4 G-CSF
  • 1.4.5 Others
• 4.2 By Type, Global Oncology Biosimilars Market Size, 2019-2021
  • 4.2.1 By Type, Global Oncology Biosimilars Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Oncology Biosimilars Price, 2020-2021

5 Impact of Covid-19 on Oncology Biosimilars Segments, By Application

• 5.1 Overview
  • 5.5.1 Retail Pharmacies
  • 5.5.2 Hospital Pharmacy
  • 5.5.3 Online Pharmacy
• 5.2 By Application, Global Oncology Biosimilars Market Size, 2019-2021
  • 5.2.1 By Application, Global Oncology Biosimilars Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Oncology Biosimilars Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Celltrion
  • 7.1.1 Celltrion Business Overview
  • 7.1.2 Celltrion Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.1.3 Celltrion Oncology Biosimilars Product Introduction
  • 7.1.4 Celltrion Response to COVID-19 and Related Developments
• 7.2 Biocon
  • 7.2.1 Biocon Business Overview
  • 7.2.2 Biocon Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.2.3 Biocon Oncology Biosimilars Product Introduction
  • 7.2.4 Biocon Response to COVID-19 and Related Developments
• 7.3 Dr. Reddy’s Laboratories
  • 7.3.1 Dr. Reddy’s Laboratories Business Overview
  • 7.3.2 Dr. Reddy’s Laboratories Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Product Introduction
  • 7.3.4 Dr. Reddy’s Laboratories Response to COVID-19 and Related Developments
• 7.4 STADA Arzneimittel AG
  • 7.4.1 STADA Arzneimittel AG Business Overview
  • 7.4.2 STADA Arzneimittel AG Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.4.3 STADA Arzneimittel AG Oncology Biosimilars Product Introduction
  • 7.4.4 STADA Arzneimittel AG Response to COVID-19 and Related Developments
• 7.5 Intas Pharmaceuticals
  • 7.5.1 Intas Pharmaceuticals Business Overview
  • 7.5.2 Intas Pharmaceuticals Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.5.3 Intas Pharmaceuticals Oncology Biosimilars Product Introduction
  • 7.5.4 Intas Pharmaceuticals Response to COVID-19 and Related Developments
• 7.6 Pfizer
  • 7.6.1 Pfizer Business Overview
  • 7.6.2 Pfizer Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.6.3 Pfizer Oncology Biosimilars Product Introduction
  • 7.6.4 Pfizer Response to COVID-19 and Related Developments
• 7.7 Sandoz International
  • 7.7.1 Sandoz International Business Overview
  • 7.7.2 Sandoz International Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.7.3 Sandoz International Oncology Biosimilars Product Introduction
  • 7.7.4 Sandoz International Response to COVID-19 and Related Developments
• 7.8 Teva Pharmaceutical Industries Ltd
  • 7.8.1 Teva Pharmaceutical Industries Ltd Business Overview
  • 7.8.2 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Introduction
  • 7.8.4 Teva Pharmaceutical Industries Ltd Response to COVID-19 and Related Developments
• 7.9 Apotex
  • 7.9.1 Apotex Business Overview
  • 7.9.2 Apotex Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.9.3 Apotex Oncology Biosimilars Product Introduction
  • 7.9.4 Apotex Response to COVID-19 and Related Developments
• 7.10 BIOCAD
  • 7.10.1 BIOCAD Business Overview
  • 7.10.2 BIOCAD Oncology Biosimilars Quarterly Production and Revenue, 2020
  • 7.10.3 BIOCAD Oncology Biosimilars Product Introduction
  • 7.10.4 BIOCAD Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Oncology Biosimilars Supply Chain Analysis
  • 8.1.1 Oncology Biosimilars Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Oncology Biosimilars Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Oncology Biosimilars Distribution Channels
  • 8.2.2 Covid-19 Impact on Oncology Biosimilars Distribution Channels
  • 8.2.3 Oncology Biosimilars Distributors
• 8.3 Oncology Biosimilars Customers

9 Key Findings

10 Appendix

• 10.1 About Us